Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.

Abstract

INTRODUCTION Rituximab has significantly improved the prognosis for patients with both indolent and aggressive non-Hodgkin's lymphoma. An economic evaluation was carried out to assess the cost-effectiveness in Sweden of rituximab as maintenance therapy for patients with follicular lymphoma in remission after second line therapy. MATERIALS AND METHODS The… (More)
DOI: 10.1080/02841860802120028

Topics

Cite this paper

@article{Kasteng2008CosteffectivenessOM, title={Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.}, author={Frida Kasteng and Martin Erlanson and Hans Hagberg and Eva K Kimby and Thomas Relander and Jonas Lundkvist}, journal={Acta oncologica}, year={2008}, volume={47 6}, pages={1029-36} }